Detalle Publicación

ART%EF%BF%BD%EF%BF%BDCULO

Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer.

Autores: Poveda, A; Del Campo, J M; Ray-Coquard, I; Alexandre, J; Provansal, M; Guerra Alia, E M; Casado, A; González Martín, Antonio; Fernandez, C; Rodriguez, I; Soto, A; Kahatt, C; Fernandez Teruel, C; Galmarini, C M; Perez de la Haza, A; Bohan, P; Berton-Rigaud, D
Título de la revista: ANNALS OF ONCOLOGY : OFFICIAL JOURNAL OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY
ISSN: 1569-8041
Volumen: 28
Número: 6
Páginas: 1280-87
Fecha de publicación: 2017
Resumen:
PM01183 is an active drug in platinum-resistant/refractory ovarian cancer and warrants further development. The highest activity was observed in platinum-resistant disease. Its safety profile indicates the dose should be adjusted to body surface area (mg/m2).
DOI: https://doi.org/10.1093/annonc/mdx111
Impacto:
42 citas en
Google Scholar